View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

AstraZeneca PLC - September 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

Thematic - 2026 Outlook - "5 More Years" (55pgs)

For access to the full note, please contact Naresh Chouhan ( ) With EU Pharma (ex-Novo) now having reached decade high valuations vs EuroStoxx600, we believe the sector has broken out & the sustainability of the growth profile will now generate continued strong performance. Consensus 5yr sales & EPS CAGR’s stand at 4% & 7% for 15x 2026 PE. We show there is upside to this from underestimated pipelines where cons. rarely fully models “monster” drugs & from M&A which we expect to be strong at JPM ...

Pfizer Inc. - September 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Johnson & Johnson: 1 director

A director at Johnson & Johnson bought 1,250 shares at 206.150USD and the significance rating of the trade was 82/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...

Johnson & Johnson - September 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Coasting as We Stalk for Buying Opportunity; Downgrading Discretionary to Underweight We had been near-term bullish on the S&P 500 (SPX) since our 4/22/25 Compass, however, we are officially downgrading our near-term outlook to neutral. The SPX, Nasdaq 100 (QQQ), and Russell 2000 (IWM) are breaking below their 50-day MAs and are also violating their multi-month uptrends, signaling a consolidation period is here. With that said, our intermediate-term outlook remains bullish (as of our 5/14/25 Co...

Moody's Ratings assigns A2 rating to Pfizer's notes; outlook stable

Moody's Ratings (Moody's) assigned a A2 rating to the new senior unsecured notes offering of Pfizer Inc. (Pfizer). There are no changes to Pfizer's existing ratings including the A2 long-term issuer rating, the A2 senior unsecured notes, the A2 senior unsecured revolving credit facility, or the Prim...

AstraZeneca: 1 director

A director at AstraZeneca sold 7,500 shares at 177.269USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

Martial Descoutures
  • Martial Descoutures
Martial Descoutures
  • Martial Descoutures
Martial Descoutures
  • Martial Descoutures
Martial Descoutures
  • Martial Descoutures

Pfizer Inc.: Update to credit analysis

Our credit view of this issuer reflects its good scale, diversity and pipeline opportunities, weighed against its large patent exposures towards the end of the decade.

Johnson & Johnson: Key facts and statistics - LTM June 2025

A summary company profile, detailing Johnson & Johnson’s business operations and financial highlights.

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch